OncoMatch/Colorectal Cancer (CRC)/NRAS
Colorectal Cancer (CRC)NRAS Clinical Trials
NRAS mutations occur in approximately 5% of colorectal cancers and, like KRAS mutations, predict resistance to anti-EGFR antibody therapy. NRAS-mutant CRC has historically lacked dedicated targeted therapies. Clinical trials explore MEK/ERK pathway inhibition, novel RAS effector strategies, and immunotherapy combinations for this subgroup.
Top recruiting NRAS Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Assistance Publique - Hôpitaux de Paris
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Caigang Liu
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
More NRAS Colorectal Cancer (CRC) trials
10 international trials (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.